Safety testing of metabolites: Expectations and outcomes.
about
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.Metabolites in safety testing.Overview of metabolite safety testing from an industry perspective.The early estimation of circulating drug metabolites in humans.Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques.
P2860
Safety testing of metabolites: Expectations and outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety testing of metabolites: Expectations and outcomes.
@en
Safety testing of metabolites: Expectations and outcomes.
@nl
type
label
Safety testing of metabolites: Expectations and outcomes.
@en
Safety testing of metabolites: Expectations and outcomes.
@nl
prefLabel
Safety testing of metabolites: Expectations and outcomes.
@en
Safety testing of metabolites: Expectations and outcomes.
@nl
P1476
Safety testing of metabolites: Expectations and outcomes
@en
P2093
K Sandy Pang
P356
10.1016/J.CBI.2008.09.013
P50
P577
2008-09-23T00:00:00Z